WO2002020040A1 - Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same - Google Patents

Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same Download PDF

Info

Publication number
WO2002020040A1
WO2002020040A1 PCT/KR2001/001492 KR0101492W WO0220040A1 WO 2002020040 A1 WO2002020040 A1 WO 2002020040A1 KR 0101492 W KR0101492 W KR 0101492W WO 0220040 A1 WO0220040 A1 WO 0220040A1
Authority
WO
WIPO (PCT)
Prior art keywords
concatemer
peptide
mimetic
apolipoprotein
epitope
Prior art date
Application number
PCT/KR2001/001492
Other languages
French (fr)
Inventor
Hyo-Joon Kim
Hae-Jung Joung
Original Assignee
Kim Hyo Joon
Joung Hae Jung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002389739A priority Critical patent/CA2389739A1/en
Priority to JP2002524523A priority patent/JP2004508029A/en
Priority to AU86286/01A priority patent/AU8628601A/en
Priority to DE60143300T priority patent/DE60143300D1/en
Priority to BR0107175-0A priority patent/BR0107175A/en
Priority to AT01965715T priority patent/ATE485053T1/en
Priority to SK631-2002A priority patent/SK6312002A3/en
Priority to HU0203251A priority patent/HUP0203251A2/en
Priority claimed from KR10-2001-0054005A external-priority patent/KR100472841B1/en
Priority to EP01965715A priority patent/EP1315517B1/en
Priority to EEP200200238A priority patent/EE200200238A/en
Priority to IL14937901A priority patent/IL149379A0/en
Priority to MXPA02004505A priority patent/MXPA02004505A/en
Application filed by Kim Hyo Joon, Joung Hae Jung filed Critical Kim Hyo Joon
Publication of WO2002020040A1 publication Critical patent/WO2002020040A1/en
Priority to BG106655A priority patent/BG106655A/en
Priority to NO20022147A priority patent/NO20022147L/en
Priority to US10/378,707 priority patent/US6825318B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates to a vaccine composition for treatment of obesity. More particularly, the present invention is directed to a vaccine composition which comprises mimetic peptide epitope of apolipoprotein B-100, concatemers or modified peptides thereof.
  • Blood serum lipid is composed of cholesterol, triglycerides (TG) , free fatty acid, phospholipid and the like, and exist in blood stream in the form of lipoprotein which is complex of lipid and apolipoprotein.
  • TG triglycerides
  • LDL low density lipoprotein
  • LDL-cholesterol a major etiological factor for adult disease related to lipid metabolism, may be converted to the form of high density lipoprotein (HDL) by macrophage.
  • HDL high density lipoprotein
  • LDL-cholesterol may also be converted to another material or be converted to the form of bile acid in the liver.
  • Apolipoprotein B-100 is a major protein part of
  • LDL-cholesterol in blood may be removed through phagocytosis by macrophage in case that an antibody in blood stream is induced by recognizing the apolipoprotein B-100, since apolipoprotein B-100 leads LDL particles to bind to LDL-receptors exposed on the cell surface (Dalum I., et al., 1997, Mol . Immunol . , 34(16-17): 1113-20).
  • IgM immunoglobin M
  • the present inventors have found that obesity can be effectively prevented by mimetic peptide epitope of apolipoprotein B-100, and based on the above, have developed a vaccine composition for treatment of obesity. Disclosure of invention
  • the object of the present invention is to provide a mimetic peptide for the epitope of apolipoprotein B-100, concatemer and modified peptides thereof.
  • Another object of the present invention is to provide a process for preparing the above mimetic peptide for the epitope of apolipoprotein B-100, concatemer and modified peptides thereof.
  • Yet another object of the present invention is to provide a vaccine composition for treatment or prevention of obesity, which comprises the above mimetic peptide for the epitope of apolipoprotein B- 100, concatemer and modified peptides thereof.
  • the object of the present invention is achieved by providing a mimetic peptide for the epitope of apolipoprotein B-100, concatemer and modified peptides thereof.
  • a peptide library system of phage was employed in the present invention in order to screen an epitope of human apolipoprotein B-100 bound by monoclonal antibody (MabB23) .
  • the screened peptides in the above were mimetic peptides structurally similar to antigenic determinant which can be recognized by the antibody, and these mimetic peptides were synthesized according to the amino acid seguence of the screened peptide.
  • Peptide library system is a kind of process for searching a three dimensional form of antigenic determinant. That is, DNA fragments which encode random-sequenced peptides are inserted into DNAs which encodes minor coat protein of phage, and then the above DNAs are inserted into RF (Reading frame) DNA and transformed to E. coli in order to express them. The peptides expressed on the surface of E.coli, are reacted with antigen in order to screen the peptides structurally similar to the antigenic determinant.
  • RF Reading frame
  • mice was immunized by introducing the above mimetic peptides. It was confirmed that the anti-serum thus obtained recognizes the original apolipoprotein B-100, mimetic peptides and LDL at the same times ( Identification of Antigenic Determinants for the Murine Monoclonal Antibodies against Apolipoprotein A-l and Apolipoprotein B-100 by using Phage-displayed Random Peptide library, Chi-Hoon Kim, Hanyang Univ., 1997).
  • the mimetic peptide for the epitope of apolipoprotein B-100 of the present invention can be selected from peptides of SEQ. ID. No.l, SEQ. ID. No.2, SEQ. ID. No.3 or the mixtures thereof.
  • the mimetic peptides of the present invention may be used in the form of concatemer in order to improve their antigenic determinant.
  • two or more mimetic peptides may be linked with each other.
  • the concatemer composed of three (3) to fifteen (15) peptides is desirable. More preferably, the concatemer of the present invention comprises four (4) peptides of SEQ. ID. No. 1.
  • Concatemer of the above mimetic peptide of the present invention refers to a polymer wherein the ends of the above mimetic peptides are linked with each other.
  • the modified peptide of the above mimetic peptide of the present invention refers to mimetic peptides variants which can be recognized by monoclonal or polyclonal antibody for apolipoprotein B-100. Such variants include substitutions, deletions, addition, and chemical substitutions of one or more amino acid from the mimetic peptide of the present invention.
  • Yet another object of the present invention is to provide a method for preparing mimetic peptide, concatemer and modified peptides thereof, which comprises: i) a step for inserting DNAs which encodes the above mimetic peptide, concatemer and the modified peptide thereof into a vector, ii ) a step for transforming the above vector to host cells, and then incubating them, and iii) a step for isolating the above mimetic peptide, concatemer or modified peptides thereof from the above host cells.
  • Formulation of the vaccine composition may be prepared through any conventional method with the mimetic peptide, concatemer or modified peptides thereof of the present invention.
  • the composition wherein the active compound mixed or diluted with immune adjuvant, drug for reinforcing immunity, carrier, expient and diluent is selected from the group consisting of tablet, pill, granule, powder, cachet, suspension, emulsion, liquid, syrup, aerosol, soft or hard gelatin capsule, sterilized liquid for injection, sterilized powder and the likes.
  • Immune adjuvant which may be employed in the composition of the present invention, is a sort of proteins containing the epitope of T cell (e.g. surface protein of hepatitis B virus) , inert carrier such as aluminium salt, bentonite, latex, acrylic particle and the like; hydrophobic antigen (e.g. lipid) , water-oil and oil-water emulsions, depot former (e.g. polysaccharide), T cell activator such as
  • B cell activator e.g. B cell mitogen
  • sulfactant such as saponin, lysolecithin, retinal, quil A, liposome and the likes
  • material for reinforcing activity of macrophage and alternative pathway complement activators such as inulin, zy osan, endotozin, lebamisole, C. parvum and the likes.
  • Carrier protein of the present invention means a pharmaceutically allowable material such as protein or aluminium salt which can transport the mimetic peptide, concatemer and modified peptides thereof of the present invention through blood stream.
  • composition of the present invention may further comprise a filler, an anti- cohesive agent, a lubricant, a moisturizer, a perfume, an emulsifier and an antiseptic.
  • composition of the present invention may be formulated by the conventional method well-known in this field to induce immune response on mammal through one(l) time or more inoculation.
  • the vaccine composition for the treatment of obesity of the present invention may be administered through various routes such as oral, dermal, intradermal, venous or muscular administration, preferably, the intradermal administration.
  • the effective dose of the vaccine composition of the present invention is 0.1 to 10 ⁇ g (active peptide) per kg of body weight, preferably, 0.5 to 1.0 ⁇ g per kg.
  • the actual dosage of the active principle of the vaccine composition may be determined depends on several factors such as condition of immunity, administration routes, condition of patient, age, sex, body weight and the like. Therefore, the ranges of the said dosage amount do not limit the scope of the present invention in any way.
  • the primary pharmaceutical effect of the vaccine composition of the present invention is to prevent or treat obesity through the mechanism that human antibody induced by mimetic peptide, concatemer or modified peptides thereof, binds on the epitope of apolipoprotein B-100 on the surface of LDL, and thereby hinders sterically and inhibits lipase from the generation of fatty acids, the major etiological factor for obesity.
  • the vaccine composition of the present invention has an effect also on suppressing hyperlipoidemia through the mechanism wherein LDL is detected and removed easily by macrophage through the opsonization caused by the human antibody induced by mimetic peptide, concatemer or modified peptides thereof and conjugated on the epitope of apolipoprotein B-100 on the surface of LDL.
  • composition of the present invention is to prevent or treat obesity by inhibiting accumulation of lipid as like cholesterol of free fatty acid in cell - through the mechanism wherein human antibody induced by mimetic peptide, concatemer or modified peptides of the present invention binds to the epitope of apolipoprotein B-100 on the surface of LDL, and thereby prohibits LDL from binding specifically to LDL receptor exposed on cell surface.
  • Fig. la to Id represent the structures and compositions of vector for expressing the mimetic peptide of the present invention.
  • Fig la represents the structure of leader cassette
  • Fig lb represents the structure of LB cassette
  • Fig lc represents the structure of BL cassette
  • Fig Id represents the structure of pBX4 expression vector.
  • Fig.2 represents the procedures for preparation of pBXl and pBX4 vector for expressing the mimetic peptide of the present invention.
  • Fig.3 represents the result of polyacrylamide gel electrophoresis (PAGE) for the identification of LB cassette.
  • Fig.4 represents the result of PAGE for the identification BL cassette incorporated in plasmid pBlue-BL.
  • Fig.5 represents the result of PAGE for the confirmation of the direction and the number of copy of DNA inserted in plasmid pBXl and pBX3.
  • Fig. 6 represents the result of western-blotting for identification of the expressed PB1 peptide.
  • Fig. 7 represents the result of sodiumdodecyl sulfate (SDS) PAGE for confirmation of the purified PB1 peptide.
  • Fig. 8 represents the result of western-blotting for confirmation of the reactivity of the purified PB1 peptide against anti-PBl serum.
  • Fig. 9 represents the result of ELISA for measurement of the avidity of the antibody of mouse induced by PB1 peptide.
  • Fig. 10 is the graph which illustrates the suppressing effect of PB1 on the increase of body weight of mouse.
  • Fig. 11a and lib are the graph illustrating the change of body weight of mice depends on administration of PB1 vaccine of the present invention in 20 weeks after injection of drug which can destroy of hypothalamus .
  • Fig. 12 is the graph which represents the effect on the concentration of lipid in blood serum according to the injection of PB1 vaccine.
  • Example 1 synthesis and annealing of oligonucleotide
  • oligonucleotides were chemically synthesized at Genemed Synthesis, Inc. (San Francisco, CA, USA) in accordance with the sequence requested from the present inventor.
  • 50z ⁇ of lQ0pmol/ t£ oligonucleotide was incubated with lO ⁇ l of lO M ATP, 3 ⁇ l of 10U/ T4 polynucleotide kinase (Takara, Otsu, Japan) and Ifd of 10X kinase buffer for two (2) hours at 37°C.
  • Ligation mixture was prepared by mixing I ⁇ JL of vector DNA, ⁇ i of insert DNA, ⁇ l of T4 DNA ligase (NEB, Beverly, MA, USA) , lfd of 10X enzyme reaction buffer solution (NEB, Beverly, MA) and 2 ⁇ & of distilled water, and then incubated at 16°C during the night and then incubated.
  • Example 3 construction of pBX expression vector for expression of mimetic peptide of apolipoprotein B- 100
  • Step 1 design of the vector
  • the plasmid vector for expression of mimetic peptide generally comprises a leader cassette and one or more PBl peptide gene.
  • the plasmid pBXl which comprises one(l) PBl gene was prepared by cloning the leader cassette (Fig. la) at the multicloning site of pQE30 plasmid (Qiagen, Hilden, Germany) .
  • the resulting plasmid was digested with Hindi 11 and Sail and the small fragment was replaced by the LB cassette (Fig. lb) to give the plasmid pBXl which is good for the insertion of multiple numbers of BL cassettes (Fig. lc) easily.
  • Leader cassette was prepared by annealing SEQ. ID.
  • the above leader cassette was designed to comprise a recognition site (DDDDKI; SEQ. ID. No.12) for enterokinase in order to reduce the additional amino acid to a minimum.
  • Example 1 According to the process of Example 1, four oligonucleotides of which sequences were represented by SEQ. ID. No. 4 to 7, were synthesized, phosphorylated, and then, annealed with complementary oligonucleotides respectively in order to synthesize the LB cassette of Fig. lb (SEQ. ID. No.13 and 14). Forty micro-litter of the annealed oligonucleotides were mixed with 3 ⁇ Jt of 1 ⁇ / ⁇ i T4 DNA ligase, 5 ⁇ i of 10X enzyme buffer and 2 ⁇ A of distilled water to prepare ligation mixture. Then, the ligation mixture was incubated during the night to link the oligonucleotides each other.
  • the reaction mixture was loaded onto 20% polyacrylamide gel and electrophoresed.
  • the LB cassette 52 bp oligonucleotides (Fig. 3) was identified by dying the gel with ethidium bromide (EtBr) .
  • lane M was a mark for 20 bp ladder
  • LB cassette was obtained from the gel by means of QIAEX II gel extraction kit (Qiagen, Hilden, Germany) .
  • the prepared expression vector was named pBXl and the peptide expressed by the vector was named PBlt peptide (refers to Fig.2) .
  • Step 3 preparation of expression vector for PBlt peptide concatemer
  • four oligonucleotides of which sequences shown at SEQ. ID. No. 4, 5, 8, and 9, were synthesized, phosphorylated and then, annealed with complementary oligonucleotides respectively in order to synthesize BL cassette of Fig. lc(SEQ.ID.No.l5 and 16).
  • oligonucletides were ligated with each other like the process of Step 2 and then were loaded onto 20% polyacrylamide gel for electrophoresis.
  • Fifty five bp oligonucleotide (leader cassette) was identified by staining the gel with EtBr.
  • BL cassette was obtained from the gel through QIAEX II gel extraction kit and cleaved by Sail and Xhol .
  • pBluescript II SK (Stratagene, La Jolla, CA, U.S.A) was cleaved by Sail and Xhol.
  • the vector was electrophoresed on 0.8% agarose gel, and obtained by means of QIAEX II gel extraction kit (Qiagen, Hilden, Germany) .
  • pBlue-BL plasmid Same ligation reaction as Example 2 was carried out to obtain pBlue-BL plasmid by using 5 ⁇ Jt of BL cassette DNA and l ⁇ of the above cleaved-vector DNA.
  • the pBlue-BL was cleaved by Sail and Xhol , and the BL cassette was extracted.
  • Plasmid pBX2 was prepared by inserting such BL cassette into the Sail site of the pBXl vector prepared in Step 2.
  • pBX3 and pBX4 vector were prepared by changing the number of the BL cassette which inserted into the Sail site of the pBXl vector from two (2) to three (3) (refers to Fig. 2).
  • the peptides expressed from the pBX2, pBX3 and pBX4 vector were a concatemer which comprises two (2) to four (4) PBl peptides. They were named PB1 2 , PB1 3 and PB1 respectively.
  • Step 4 Identification of the insert Host cell (E. coli M15 [pREP4] ; Qiagen, Hilden, Germany) was transformed with the pBlue-BL plasmid and spread onto 1% agar plate, and then incubated for 16 hours at 37 ° C so that colonies of E. coli could be formed.
  • One of the colonies which had been formed on the agar plate was inoculated in lOm ⁇ , of LB medium and incubated with shaking at 37 °C for sixteen (16) hours, and then the plasmid was isolated through DNA purification system (Wizard PLUS SV DNA miniprep DNA purification system; Promega, Madison, WI, U.S.A). The plasmid harvested from the transformed E.
  • coli was incubated with Sail and Xhol restriction enzyme in order to be cleaved at 37°C for one(l) hour, and analyzed through 20% PAGE(Fig. 4).
  • lane M represents 20 bp ladder DNA
  • lane 1 represents oligonucleotide product obtained from Step 3
  • lane 2 represents BL cassette DNA isolated by 20% PAGE from step3
  • lane 3 represents recombinant pBlue-BL plasmid treated with restriction enzyme.
  • E. coli (M15 [pREP4] ) was transformed with pBXl or pBX3 plasmid, and the plasmid DNA was isolated as explained above in order to confirm the number and orientation of the DNA cassette inserts.
  • the isolated plasmid was cleaved by Sail and HindiII restriction enzyme, and analyzed through 20% PAGE (Fig. 5).
  • lane M represents 20 bp ladder DNA
  • lane 1 and 3 represent the pBXl plasmid containing an LB but not BL cassette
  • lane 2 represents the plasmid harboring one LB and two BL cassettes with the right direction.
  • lane 4 represents the plasmid having one LB and two BL cassettes, however, with reversed orientation. As shown in Fig. 5, how many B cassettes
  • Step 1 confirmation of expression of PB1 4 peptide
  • three kinds of transformed E. coli Ml5[pREP4] were cultivated on LB agar broth containing amphicillin and kanamycin.
  • E. coli M15[pREP4] was transformed with the plasmid pBX4, another was mock transformed with pQE30, and the other was not transformed E. coli M15[pREP4].
  • Each colonies formed from the solide culture was inoculated respectively in liquid LB culture medium which contained 100/t ⁇ /m£ amphicillin and 25 ⁇ /m# kanamycin, and incubated overnight. The culture was incubated at 37 ° C for one(l) hour with shaking until the O.D value reached in the scope of 0.5 to 0.7 at 600nm.
  • IPTG isopropyl-thio- ⁇ -galactopyranoside
  • SeeBlue 250Kda to 4kDa; NOVEX, San Diego, CA, U.S.A
  • wide-ranging standard Markl2 200kDa to 2.5kDa
  • decolorizing solution 5% Methanol and 7% acetic acid
  • lane M represents the pre-stained standard SeeBlue label
  • lane 1 represents medium used for incubation of E. coli M15 [pREP4] which was not transformed
  • lane 2 represents medium used for incubation of E. coli M15 [pREP4] which was transformed with pQE30 vector
  • lane 3 represents medium used for incubation of E.
  • Step 2 Identification of solubility of the expressed peptide
  • Step 1 10ml of the culture medium was taken and centrifuged to harvest the cells.
  • the cell pellet was suspended in 5ml of cell lysis solution (300mM NaCl, 50mM NaH 2 P0, lOmM imidazol pH 8.0) to obtain natural protein from the cell.
  • cell lysis solution 300mM NaCl, 50mM NaH 2 P0, lOmM imidazol pH 8.0
  • the pellet-suspended solution was sonicated 20 cycles with ultrasonic wave in order to lyse the cells.
  • the supernatant was taken by centrifuge at 4 ° C, 10,000r ⁇ m for 30 min..
  • the same volume of 2X SDS solution was mixed with solution and SDS-PAGE was carried out as the same method described in Step 1. After boiling each solution at 95°C for 5 min.
  • Step 3 purification of PB1 4 peptide
  • Step 3-1 affinity chromatography Ni-NTA resin for purifying His-tagged proteins, was used to purify the recombinant peptide in Step 1.
  • coli M15[pREP4] which had been transformed with pBX4, was inoculated in 11 of LB culture medium and incubated at 37 °C to the extent that O.D value was over 0.6 at 600nm.
  • the ratio of LB culture medium to pBX4 vector was fifty (50) to one(l).
  • IPTG was added in a final concentration of ImM and incubated again for five (5) hours. After incubation, the cell pellet was obtained by centrifuging the culture medium at 6,000 Xg for 30 min, and the pellet was stored at -70 ° C over night. The pellet thawed in ice, was suspended in dissolving solution (300mM NaCl,
  • Cells are lyzed by sonication as the method of Step 2, and then centrifuged at room temperature at 10,000 Xg for 30 min..
  • the suspension was centrifuged at 8,000rpm for 30 min. to remove cellular debris which had not been solubilized in 8M urea.
  • lm-C of Ni-NTA resin was added at 4°C and shook 200rpm for 2 hours in order proteins containing His-tag to be captured.
  • the target proteins containing His-tag were eluted by pouring 5mi of low pH buffer (8M urea, 0.1M NaH 2 P0 4 0.01M Tris-HCl pH 5.9) two (2) times and subsequently 5mi of strong acid buffer (8M urea, 0.1M NaH 2 P0 4 0.01M Tris-HCl pH 4.5) four (4) times, and then SDS-PAGE was used to confirm the eluted target proteins by using 15% acryamide gel (Fig. 7).
  • lane M represents pre-stained SeeBlue size marker and lane 1 represents the purified PB1 4 peptide.
  • the above purified proteins are dialyzed against PBS(8g/L NaCl, 0.2g/L KC1, 1.44g/L Na 2 HP0 4 and 0.24g/L KH 2 P0 ) in order to regain their original conformations.
  • Dialysis tube employed was 3,500 Da in molecular weight cut-off size. During dialysis, 3L of PBS containing 2M urea was used first for 5 hours, and then 5L of PBS without urea was used two (2) times overnight .
  • Step 3-2 Hydrophobic chromatography
  • Ammonium sulfate was added up to final 20% concentration little by little to the solution containing PB1 4 peptide, which was eluted from Ni-NTA resin in Step 3-1, and then adjusted to pH 7.0. The solution was left for three or more hours after 10% of ammonium sulfate had been melt completely, and then the solution was loaded on the phenyl sepharose column [a filling: Phenyl sepharose Fast Flow resin (Phamacia, Suweden) ; column size: 1 cm(id) x 3cm(h)]. Each fraction which was eluted from the column by pouring eluting solution (8M urea, 0.
  • 2M urea was added to buffer solution (50mM NaCl, 20mM Tris-HCl, 2mM CaCl 2 pH7.4 ) which was good for removing denaturating agent and imidazol etc. from the purified his-tagged protein and also for activating enterokinase.
  • the dialyzed PB1 4 peptide which had been obtained from Step 3-2, was dialyzed again by using the above urea containing buffer to desalt the PB1 4 peptide, and during which, the concentration of urea was lowered little by little by repeated dialysis against urea depleted buffer.
  • enterokinase was added to the PB1 peptide-containing solution of which buffer was changed with the said second buffer, and incubated at 23 ° C. The solution which was taken at every hour, then was analyzed by SDS-PAGE in order to check the amount of his-tag removal from the his- tagged PB1(PB1 4 +his ) peptide.
  • Step 3-4 Ion exchange chromatography Unwanted proteins and peptides which had been produced as a result of treatment of enterokinase, were removed through ion exchange chromatography.
  • Step 4 Quantitative analysis f PB1 4 The purified PB1 4 peptide which had been obtained through the same method of Step 3, was quantitatively analyzed through colorimetric analysis by using micro BCA reagent (Pierce, Rockford, USA).
  • Step 5 Confirmation of characteristics of the recombinant PB1 4 peptide
  • the blotted membrane was incubated with a 5ml of blocking solution (TBS pH 7.5, 5% skim milk powder (w/v), 0.02% Tween 20) for 1.5 hours, and then was washed three times with TTBS (Tris-buffered saline solution containing 0.1% Tween 20) for 15 min.,
  • TBS Tris-buffered saline solution containing 0.1% Tween 20
  • the antiserum against the peptide PBl (refers to Step 1 of Example 2) was diluted with the TTBS solution in ratio of one (1) to five thousand (5,000), and then incubated with the membrane for 1.5 hours. To confirm the purity of the peptide PBl (refers to Step 1 of Example 2) was diluted with the TTBS solution in ratio of one (1) to five thousand (5,000), and then incubated with the membrane for 1.5 hours. To confirm the purity of the TTBS solution.
  • Example 3 After washing the gel with TTBS three times for 15 min., 5 min. and 5 min in turn, the membrane was incubated for 1.5 hours at room temperature with the solution in which alkaline phosphatase-F (ab) ' 2 -goat anti-mouse IgG (H+L) (Zymed, San Fransisco, CA) was diluted with the TTBS solution in ratio of one(l) to one thousand(lOOO) . The membrane was washed again with TTBS three times, and then colorized by adding BCIP/NBT (5-bromo-4-chloro-3- indolyl phosphate/nitro blue tetrazolium(Sigma) ) . BCIP/NBT solution was removed using TTBS solution after staining. As a result of western-blotting analysis, the expressed PB1 peptide could be recognized with the anti-PBl 4 serum.
  • BCIP/NBT 5-bromo-4-chloro-3- indolyl phosphate
  • PVDF membrane (Gel an Science, BioTrace R ) was used instead of nitrocellulose membrane.
  • the first antibody was used in ratio of one(l) to ten thousand(10, 000) and HRP-conjugated rabbit anti-mouse IgG (Pierce, Rockford, IL, U.S.A.) was used as the second antibody in ratio of one(l) to ten thousand(10,000) .
  • lane M represents a ECL detecting label (Gibco BRL) and lane 1 represents the PB1 4 peptide.
  • lane 1 represents the PB1 4 peptide.
  • the expressed PB1 4 peptide could be recognized with the anti-PBl 4 serum.
  • Example 5 Preparation of anti-PBl4 peptide mouse antibody
  • the PB1 4 peptide used herein was the PBl 4 "his peptide from which his-tag was removed, in step 3-3 of example 2.
  • Step 1 Ligation between PB1 peptide and OVA
  • OVA ovalbumin
  • a carrier protein ovalbumin
  • OVA ovalbumin
  • PBI4 peptide-ovalbumin solution 2% (v/v) glutaraldehyde was added with the same volume, and incubated for one (1) hour with continuous shaking. Then glycine was added to the reaction mixture until final concentration is to be 0.2M to stop the reaction proceeding therein.
  • Step 2 Immunization of mouse
  • the peptide with which OVA was linked in Step 1 was concentrated and used to immunize mouse.
  • the amount of the antigen to be injected to the mouse was 5ug which was the amount of PBI4 peptide before linked with OVA.
  • the antigen which was emulsified with the same amount of an adjuvant was injected to intraperitoneum cavity of the mouse in amount of 0.2ml.
  • Complete Freund's Adjuvant (CFA) was used as the adjuvant of the first injection
  • IFA Incomplete Freund's Adjuvant
  • BSA bovine serum albumin
  • Step 3 Measurement of avidity of anti-PBl antibody by indirect ELISA
  • the avidity of the antibody was measured by using blood serum obtained in Step 2. lOOul of PB1 4 peptide was distributed into each well of 96 well micro-titer plate (Flacon: pro-binding) and left alone at 4 ° C for 6 hours or more, and then washed three (3) times with
  • TTBS Tetramethyl methylcholine
  • TTBS Tetramethyl methylcholine
  • 200ul of blocking solution 1% BSA in TTBS was added to each well and incubated at 37 °C for one
  • Solution A of the HRP substrate kit (Bio-Rad) was mixed with solution B of the same in ratio of nine (9) to one (1) .
  • lOOul of the resultant mixture was added to the reaction solution and colorized for thirty (30) min., and then optical absorbency for the reaction mixture was measured at 405nm by using ELISA leader (EL312e, Bio-Tek Ins.) (Fig.9).
  • ELISA leader EL312e, Bio-Tek Ins.
  • Example 6 Anti-obesity effect of PB1 4 vaccine by using a mouse model.
  • Step 1 Induction of obesity in a mouse
  • mice were raised in a breeding farm in which temperature was kept from 17 ° C to 25 ° C, and fed to a mixed feed (Sam Yang Feed Ltd., Seoul, Korea,
  • GTG Goldthioglucose
  • VMH ventero- medial hypothalamic nuclei
  • mice were distributed to prepare a test (twenty (20) mice) .and a control group (four (4) mice), and 25ml of GTG was injected to the test group whereas the control was injected with nothing.
  • Body weight of the mice of the test group was measured prior to experiment and the mice of which deviation of body weight was not significant, were selected and applied to experiment.
  • Body weight of the mice measured after one (1) week after GTG injection was in the range from 26.5 to 29.5grams.
  • mice of -the GTG-injected group were induced to be obese whereas the remainder was not.
  • the mice which were not induced to be obese was injected again with GTG, then all the mice were induced to be obese. All of the obesity-induced mice were distributed in three (3) group.
  • a week later from second GTG injection the PB1 4 peptide was injected to the mice of test group 1 consisting of seven (7) mice as the same method in Step 2 of Example 3.
  • the mice (test group 2 containing seven (7) mice) of another group of the three were injected with ovalbumin instead of PBI4 peptide as a mock experiment, and vaccine was not injected to the other group (test group 3 containing si (6) mice) to induce obesity.
  • 0.2ml of PBS was injected to the control group to be compared with the test groups to confirm the effect of the vaccine of the present invention.
  • feed used herein was mixed with the yolk of an egg and dried at 50 ° C to induce intake of cholesterol so that the level of cholesterol could increase in mouse serum. Feed was also provided enough for disease related to the level of cholesterol to be caused.
  • Body weight of the mouse was measured everyday. As depicted in Fig. 10, body weight of the vaccine'-injected mice of test group l(-A-A-), increased from 27.7 ⁇ 0.4g to 52.2 ⁇ 1.7g after twelve weeks (12) of GTG injection. The data justify a conclusion that there was no significant difference of an increase in body weight between the test group 1 and the control group (-0-0-) .
  • Gl and G2 represent the time of GTG injection and VI, V2 and V3 represent the time of injection of PBI4 peptide vaccine.
  • Fig. 11 represents appearance of the obesity- induced mice. 20-week old mouse of the test group 1 (Fig.11a: normal mouse) was compared with 20-week old mouse of the test group 3 (Fig. llb:obese mouse). As depicted in Fig. 11, it was confirmed that the vaccine of the present invention was effective in inhibiting obesity.
  • Step 2 Measurement of the level of cholesterol in blood. After the first GTG injection, blood cholesterol level of 12-week old mouse of the control group was compared with that of 12-week old GTG-injected mouse of the test group 1 and 2. Concentration of total cholesterol, triglyceride, HDL-cholesterol and LDL- cholesterol was measured through an enzymatic method by using Cholestezyme-V, Triglyzyme-V, HDL-C555 (Shin
  • the vaccine composition of the present invention which contains mimetic peptide for the epitope of apolipoprotein B-100, the concatemers and modified peptide thereof, can be inhibit occurrence of obesity without causing auto-immunity in organism.
  • LDL-related circulatory disease can be treated by vaccine of the present invention more effective than the transitory and high-priced conventional method in which cholesterol metabolism-related enzyme was inhibited.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to vaccine compositions for treatment of obesity. More particularly, the present invention is directed to mimetic for epitope of apolipoprotein B-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same.

Description

MIMETIC PEPTIDES FOR EPITOPE OF APOLIPOPROTEIN B-100, CONCATEMER AND MODIFIED PEPTIDES THEREOF, AND THE VACCINE COMPOSITION COMPRISING THE SAME
Technical Field
The present invention relates to a vaccine composition for treatment of obesity. More particularly, the present invention is directed to a vaccine composition which comprises mimetic peptide epitope of apolipoprotein B-100, concatemers or modified peptides thereof.
Background Art
Blood serum lipid is composed of cholesterol, triglycerides (TG) , free fatty acid, phospholipid and the like, and exist in blood stream in the form of lipoprotein which is complex of lipid and apolipoprotein.
Of these lipoproteins, low density lipoprotein (LDL) is major carrier for TG and cholesterol. The number of patient suffering from arteriosclerosis, coronary artery disease, or cardiac infarction caused by elevated LDL-cholesterol level in blood, has been considerably increased due to the change of dietary life or other factors.
Therefore, various researches for lowering the level of LDL-cholesterol and for showing the cause of above diseases, have been tried to treat patients suffering from the above diseases. LDL-cholesterol, a major etiological factor for adult disease related to lipid metabolism, may be converted to the form of high density lipoprotein (HDL) by macrophage. In addition, LDL-cholesterol may also be converted to another material or be converted to the form of bile acid in the liver. (Brown, M.S. and Goldstein, J.L., 1983, Annu . Rev. Biochem . , 52:223-
261) .
Apolipoprotein B-100 is a major protein part of
LDL and exists also in very low density lipoprotein
(VLDL) and chylomicron. LDL-cholesterol in blood may be removed through phagocytosis by macrophage in case that an antibody in blood stream is induced by recognizing the apolipoprotein B-100, since apolipoprotein B-100 leads LDL particles to bind to LDL-receptors exposed on the cell surface (Dalum I., et al., 1997, Mol . Immunol . , 34(16-17): 1113-20).
In case that a macromolecule such as an antibody has been bound to apolipoprotein B-100 which exists on the surface of LDL, lipase such as lipoprotein lipase cannot hydrolize TG and the likes due to the steric hindrance caused by the macromolecule bound to apolipoprotein B-100. Conseguently, the formation of free fatty acid, a major factor for obesity, can be inhibited by means of the antibody which can bind to apolipoprotein B-100. Recently, several researches for lowering LDL- cholesterol level and for inhibiting the outbreak of arteriosclerosis by using a vaccine, have been tried in various animal models such as mouse and rabbit. For example, CR. Alving reported that cholesterol may be modified by metabolites or its oxidation, and that the modified cholesterol can be a strong antigenic determinants in some cases (Alving, C.R., et al . , 1989,
Biochem . Soc. Trans . , 17(4): 637-9; Alving, C.R., et al., 1996, J. Lab. Clin . Med. , 127: 40-49; Alving,
C.R., et al., 1996, Curr. Top. Microbiol . Immunol . , 210: 181-6) .
Furthermore, it has been reported that an endogenous antibody for cholesterol exists in blood serum (Wu, J.T., L.L., 1997, Clin. Lab. Med. , 17(3):
595-604, Review) . It has also been reported that, in the experiment wherein arteriosclerosis and hypercholesterolemia are induced on rabbit by feeding cholesterol-containing meal, the occurrence of hypercholesterolemia and arteriosclerosis in the rabbit immunized by injecting cholesterol-containing liposome, is suppressed or lowered remarkably than those in control group.
Such antibody induced by cholesterol vaccine, is immunoglobin M (IgM) which binds to VLDL, intermediate density lipoprotein (IDL) and LDL. Based on the above, it is believed that a vaccine for treatment or prevention of hyperlipoidemia or arteriosclerosis caused by high level of cholesterol,' will be possible
(Bailey, J.M., 1994, Science, 264: 1067-1068; Palinski,
W. et al., 1995, Proc. Natl. Acad. Sci. U.S.A., 92(3): 821-5; Wu, R. et al, 1999, Hypertension, 33(1): 53-9).
The present inventors have found that obesity can be effectively prevented by mimetic peptide epitope of apolipoprotein B-100, and based on the above, have developed a vaccine composition for treatment of obesity. Disclosure of invention
Therefore, the object of the present invention is to provide a mimetic peptide for the epitope of apolipoprotein B-100, concatemer and modified peptides thereof.
Another object of the present invention is to provide a process for preparing the above mimetic peptide for the epitope of apolipoprotein B-100, concatemer and modified peptides thereof.
Yet another object of the present invention is to provide a vaccine composition for treatment or prevention of obesity, which comprises the above mimetic peptide for the epitope of apolipoprotein B- 100, concatemer and modified peptides thereof.
The object of the present invention is achieved by providing a mimetic peptide for the epitope of apolipoprotein B-100, concatemer and modified peptides thereof. A peptide library system of phage was employed in the present invention in order to screen an epitope of human apolipoprotein B-100 bound by monoclonal antibody (MabB23) . The screened peptides in the above were mimetic peptides structurally similar to antigenic determinant which can be recognized by the antibody, and these mimetic peptides were synthesized according to the amino acid seguence of the screened peptide.
Peptide library system is a kind of process for searching a three dimensional form of antigenic determinant. That is, DNA fragments which encode random-sequenced peptides are inserted into DNAs which encodes minor coat protein of phage, and then the above DNAs are inserted into RF (Reading frame) DNA and transformed to E. coli in order to express them. The peptides expressed on the surface of E.coli, are reacted with antigen in order to screen the peptides structurally similar to the antigenic determinant.
In order to prepare anti-serum, mice was immunized by introducing the above mimetic peptides. It was confirmed that the anti-serum thus obtained recognizes the original apolipoprotein B-100, mimetic peptides and LDL at the same times ( Identification of Antigenic Determinants for the Murine Monoclonal Antibodies Against Apolipoprotein A-l and Apolipoprotein B-100 by using Phage-displayed Random Peptide library, Chi-Hoon Kim, Hanyang Univ., 1997).
The mimetic peptide for the epitope of apolipoprotein B-100 of the present invention, can be selected from peptides of SEQ. ID. No.l, SEQ. ID. No.2, SEQ. ID. No.3 or the mixtures thereof.
The mimetic peptides of the present invention may be used in the form of concatemer in order to improve their antigenic determinant. As an embodiment of the present invention, two or more mimetic peptides may be linked with each other. The concatemer composed of three (3) to fifteen (15) peptides is desirable. More preferably, the concatemer of the present invention comprises four (4) peptides of SEQ. ID. No. 1.
"Concatemer" of the above mimetic peptide of the present invention, refers to a polymer wherein the ends of the above mimetic peptides are linked with each other. λThe modified peptide" of the above mimetic peptide of the present invention, refers to mimetic peptides variants which can be recognized by monoclonal or polyclonal antibody for apolipoprotein B-100. Such variants include substitutions, deletions, addition, and chemical substitutions of one or more amino acid from the mimetic peptide of the present invention. Yet another object of the present invention is to provide a method for preparing mimetic peptide, concatemer and modified peptides thereof, which comprises: i) a step for inserting DNAs which encodes the above mimetic peptide, concatemer and the modified peptide thereof into a vector, ii ) a step for transforming the above vector to host cells, and then incubating them, and iii) a step for isolating the above mimetic peptide, concatemer or modified peptides thereof from the above host cells. Formulation of the vaccine composition may be prepared through any conventional method with the mimetic peptide, concatemer or modified peptides thereof of the present invention. In the process for preparing the above formulation, preferably, the composition wherein the active compound mixed or diluted with immune adjuvant, drug for reinforcing immunity, carrier, expient and diluent, is selected from the group consisting of tablet, pill, granule, powder, cachet, suspension, emulsion, liquid, syrup, aerosol, soft or hard gelatin capsule, sterilized liquid for injection, sterilized powder and the likes. Immune adjuvant which may be employed in the composition of the present invention, is a sort of proteins containing the epitope of T cell (e.g. surface protein of hepatitis B virus) , inert carrier such as aluminium salt, bentonite, latex, acrylic particle and the like; hydrophobic antigen (e.g. lipid) , water-oil and oil-water emulsions, depot former (e.g. polysaccharide), T cell activator such as
PPD, polyadenine, polyuracil and the likes; B cell activator (e.g. B cell mitogen) , sulfactant such as saponin, lysolecithin, retinal, quil A, liposome and the likes; material for reinforcing activity of macrophage; and alternative pathway complement activators such as inulin, zy osan, endotozin, lebamisole, C. parvum and the likes.
"Carrier protein" of the present invention means a pharmaceutically allowable material such as protein or aluminium salt which can transport the mimetic peptide, concatemer and modified peptides thereof of the present invention through blood stream.
Aluminium salt, phenoxyethyl ethanol, water, physiological salt solution, lactose, dextrose, sucrose, sorbitol, manitol, calcium silicate, cellulose, methyl cellulose, amorphous cellulose, polyvinylpyrolidon, metylhydroxy bezoate, propylhydroxybezoate, talc, magnesium stealate and a mineral oil may be used as suitable carriers, expients or diluents in the composition of the present invention. In addition, the composition of the present invention may further comprise a filler, an anti- cohesive agent, a lubricant, a moisturizer, a perfume, an emulsifier and an antiseptic.
The composition of the present invention may be formulated by the conventional method well-known in this field to induce immune response on mammal through one(l) time or more inoculation.
The vaccine composition for the treatment of obesity of the present invention may be administered through various routes such as oral, dermal, intradermal, venous or muscular administration, preferably, the intradermal administration.
The effective dose of the vaccine composition of the present invention, is 0.1 to 10 μg (active peptide) per kg of body weight, preferably, 0.5 to 1.0 μg per kg. However, the actual dosage of the active principle of the vaccine composition may be determined depends on several factors such as condition of immunity, administration routes, condition of patient, age, sex, body weight and the like. Therefore, the ranges of the said dosage amount do not limit the scope of the present invention in any way.
The primary pharmaceutical effect of the vaccine composition of the present invention, is to prevent or treat obesity through the mechanism that human antibody induced by mimetic peptide, concatemer or modified peptides thereof, binds on the epitope of apolipoprotein B-100 on the surface of LDL, and thereby hinders sterically and inhibits lipase from the generation of fatty acids, the major etiological factor for obesity.
In addition, the vaccine composition of the present invention has an effect also on suppressing hyperlipoidemia through the mechanism wherein LDL is detected and removed easily by macrophage through the opsonization caused by the human antibody induced by mimetic peptide, concatemer or modified peptides thereof and conjugated on the epitope of apolipoprotein B-100 on the surface of LDL.
Another pharmaceutical effect of the composition of the present invention, is to prevent or treat obesity by inhibiting accumulation of lipid as like cholesterol of free fatty acid in cell - through the mechanism wherein human antibody induced by mimetic peptide, concatemer or modified peptides of the present invention binds to the epitope of apolipoprotein B-100 on the surface of LDL, and thereby prohibits LDL from binding specifically to LDL receptor exposed on cell surface.
Brief Description of the Drawings The above objects and other advantages of the present invention will become more apparent by describing in detail a preferred embodiment thereof with reference to the attached drawings, in which:
Fig. la to Id represent the structures and compositions of vector for expressing the mimetic peptide of the present invention. Fig la represents the structure of leader cassette, Fig lb represents the structure of LB cassette, Fig lc represents the structure of BL cassette and Fig Id represents the structure of pBX4 expression vector.
Fig.2 represents the procedures for preparation of pBXl and pBX4 vector for expressing the mimetic peptide of the present invention.
Fig.3 represents the result of polyacrylamide gel electrophoresis (PAGE) for the identification of LB cassette.
Fig.4 represents the result of PAGE for the identification BL cassette incorporated in plasmid pBlue-BL.
Fig.5 represents the result of PAGE for the confirmation of the direction and the number of copy of DNA inserted in plasmid pBXl and pBX3.
Fig. 6 represents the result of western-blotting for identification of the expressed PB1 peptide.
Fig. 7 represents the result of sodiumdodecyl sulfate (SDS) PAGE for confirmation of the purified PB1 peptide.
Fig. 8 represents the result of western-blotting for confirmation of the reactivity of the purified PB1 peptide against anti-PBl serum. Fig. 9 represents the result of ELISA for measurement of the avidity of the antibody of mouse induced by PB1 peptide.
Fig. 10 is the graph which illustrates the suppressing effect of PB1 on the increase of body weight of mouse.
Fig. 11a and lib are the graph illustrating the change of body weight of mice depends on administration of PB1 vaccine of the present invention in 20 weeks after injection of drug which can destroy of hypothalamus .
Fig. 12 is the graph which represents the effect on the concentration of lipid in blood serum according to the injection of PB1 vaccine.
Best mode for carrying out the present invention
Hereinafter, the present invention will be described in more details. However, the present invention explained in below, is given only for the explanation of embodiment of the present invention and not intended to limit the scope of the present invention.
Example 1 : synthesis and annealing of oligonucleotide
The oligonucleotides were chemically synthesized at Genemed Synthesis, Inc. (San Francisco, CA, USA) in accordance with the sequence requested from the present inventor. In order to phosphorylate the 5' end of oligonucleotides, 50z^ of lQ0pmol/ t£ oligonucleotide was incubated with lOμl of lO M ATP, 3μl of 10U/ T4 polynucleotide kinase (Takara, Otsu, Japan) and Ifd of 10X kinase buffer for two (2) hours at 37°C. Each of 10 t aliquote of above phosphorylated oligonucleotides were mixed together, heated at 80°C for 5 min. and then chilled very slowly to the room temperature thus were annealed to the specific pairing between complementary strands . Example 2: ligation
Ligation mixture was prepared by mixing IμJL of vector DNA, μi of insert DNA, ±μl of T4 DNA ligase (NEB, Beverly, MA, USA) , lfd of 10X enzyme reaction buffer solution (NEB, Beverly, MA) and 2μ& of distilled water, and then incubated at 16°C during the night and then incubated.
Example 3: construction of pBX expression vector for expression of mimetic peptide of apolipoprotein B- 100
Step 1: design of the vector
The plasmid vector for expression of mimetic peptide generally comprises a leader cassette and one or more PBl peptide gene. As depicted in Fig. 1, the plasmid pBXl which comprises one(l) PBl gene was prepared by cloning the leader cassette (Fig. la) at the multicloning site of pQE30 plasmid (Qiagen, Hilden, Germany) . The resulting plasmid was digested with Hindi 11 and Sail and the small fragment was replaced by the LB cassette (Fig. lb) to give the plasmid pBXl which is good for the insertion of multiple numbers of BL cassettes (Fig. lc) easily.
Meanwhile, the plasmid pBluescript II SK+ was cut with Sail and Xhol and ligated with BL cassettes in which single to multiple BL cassette insertions occurred randomly. The expected repeats of the PBl peptide genes in the plasmid pBlue-BL were selected and cleaved oit and subcloned into pBXl (Fig. Id) . Step 2: Preparation of vector for expression of
PBl mono-peptide
Leader cassette was prepared by annealing SEQ. ID.
No.10 and SEQ. ID. No.11 oligonucleotide synthesized through the same process as Example 1 and 2. Then, the pQE30 vector (Qiagen, Hilden, Germany) , which had been cleaved by Sail and BamHI , was ligated with the above leader cassette in order to prepare pQE-Leader plasmid.
As a result of expression of the above pQE30 vector, six histidine residues were additionally incorporated to the N-terminus of the expressed protein in order for the protein to be purified easily. The above leader cassette was designed to comprise a recognition site (DDDDKI; SEQ. ID. No.12) for enterokinase in order to reduce the additional amino acid to a minimum.
According to the process of Example 1, four oligonucleotides of which sequences were represented by SEQ. ID. No. 4 to 7, were synthesized, phosphorylated, and then, annealed with complementary oligonucleotides respectively in order to synthesize the LB cassette of Fig. lb (SEQ. ID. No.13 and 14). Forty micro-litter of the annealed oligonucleotides were mixed with 3μJt of 1 ϋ/μi T4 DNA ligase, 5βi of 10X enzyme buffer and 2μA of distilled water to prepare ligation mixture. Then, the ligation mixture was incubated during the night to link the oligonucleotides each other.
After the reaction being completed, the reaction mixture was loaded onto 20% polyacrylamide gel and electrophoresed. The LB cassette (52 bp oligonucleotides) (Fig. 3) was identified by dying the gel with ethidium bromide (EtBr) .
In Fig. 3, lane M was a mark for 20 bp ladder
DNA, and lane 1 was the reaction solution. LB cassette was obtained from the gel by means of QIAEX II gel extraction kit (Qiagen, Hilden, Germany) .
The above pQE-Leader was cleaved by Hindlll and
Sail, and then ligated with the above LB cassette according to Example 2 in order to prepare expression vector for PBl mimetic peptide. The prepared expression vector was named pBXl and the peptide expressed by the vector was named PBlt peptide (refers to Fig.2) .
Step 3: preparation of expression vector for PBlt peptide concatemer According to the process of Example 1, four oligonucleotides of which sequences shown at SEQ. ID. No. 4, 5, 8, and 9, were synthesized, phosphorylated and then, annealed with complementary oligonucleotides respectively in order to synthesize BL cassette of Fig. lc(SEQ.ID.No.l5 and 16). Subsequently such oligonucletides were ligated with each other like the process of Step 2 and then were loaded onto 20% polyacrylamide gel for electrophoresis. Fifty five bp oligonucleotide (leader cassette) was identified by staining the gel with EtBr. BL cassette was obtained from the gel through QIAEX II gel extraction kit and cleaved by Sail and Xhol .
Meanwhile, a pBluescript II SK (Stratagene, La Jolla, CA, U.S.A) was cleaved by Sail and Xhol. The vector was electrophoresed on 0.8% agarose gel, and obtained by means of QIAEX II gel extraction kit (Qiagen, Hilden, Germany) .
Same ligation reaction as Example 2 was carried out to obtain pBlue-BL plasmid by using 5μJt of BL cassette DNA and lβϋ of the above cleaved-vector DNA. The pBlue-BL was cleaved by Sail and Xhol , and the BL cassette was extracted. Plasmid pBX2 was prepared by inserting such BL cassette into the Sail site of the pBXl vector prepared in Step 2. In addition, pBX3 and pBX4 vector were prepared by changing the number of the BL cassette which inserted into the Sail site of the pBXl vector from two (2) to three (3) (refers to Fig. 2).
The peptides expressed from the pBX2, pBX3 and pBX4 vector, were a concatemer which comprises two (2) to four (4) PBl peptides. They were named PB12 , PB13 and PB1 respectively.
Step 4: Identification of the insert Host cell (E. coli M15 [pREP4] ; Qiagen, Hilden, Germany) was transformed with the pBlue-BL plasmid and spread onto 1% agar plate, and then incubated for 16 hours at 37 °C so that colonies of E. coli could be formed. One of the colonies which had been formed on the agar plate, was inoculated in lOmϋ, of LB medium and incubated with shaking at 37 °C for sixteen (16) hours, and then the plasmid was isolated through DNA purification system (Wizard PLUS SV DNA miniprep DNA purification system; Promega, Madison, WI, U.S.A). The plasmid harvested from the transformed E. coli was incubated with Sail and Xhol restriction enzyme in order to be cleaved at 37°C for one(l) hour, and analyzed through 20% PAGE(Fig. 4). In Fig. 4, lane M represents 20 bp ladder DNA, lane 1 represents oligonucleotide product obtained from Step 3, lane 2 represents BL cassette DNA isolated by 20% PAGE from step3 and lane 3 represents recombinant pBlue-BL plasmid treated with restriction enzyme. As shown in
Fig. 4, it was confirmed that the pBlue-BL plasmid contained BL cassette.
E. coli (M15 [pREP4] ) was transformed with pBXl or pBX3 plasmid, and the plasmid DNA was isolated as explained above in order to confirm the number and orientation of the DNA cassette inserts. The isolated plasmid was cleaved by Sail and HindiII restriction enzyme, and analyzed through 20% PAGE (Fig. 5). In Fig. 5, lane M represents 20 bp ladder DNA, lane 1 and 3 represent the pBXl plasmid containing an LB but not BL cassette, lane 2 represents the plasmid harboring one LB and two BL cassettes with the right direction. On the other hand, lane 4 represents the plasmid having one LB and two BL cassettes, however, with reversed orientation. As shown in Fig. 5, how many B cassettes
(BL or LB cassette) were inserted and what direction they were inserted into the pBX vector, could identify restriction enzyme mapping. In addition, the DNA sequence of the B cassettes incorporated into the plasmid which had been harvested from the transformed E. coli , was confirmed to be identical to the designed sequences. The plasmids were prepared by Wizard PLUS DNA miniprep kit and were sequenced by using Sequennase (Ver. 2.1) DNA sequencing kit (Amersham, Cleveland, UK) . Example 4: Expression of PB14 peptide in E. coli and its purification.
Step 1: confirmation of expression of PB14 peptide To confirm the expression of PB14 peptide, three kinds of transformed E. coli Ml5[pREP4] were cultivated on LB agar broth containing amphicillin and kanamycin.
One E. coli M15[pREP4] was transformed with the plasmid pBX4, another was mock transformed with pQE30, and the other was not transformed E. coli M15[pREP4]. Each colonies formed from the solide culture was inoculated respectively in liquid LB culture medium which contained 100/tβ/m£ amphicillin and 25 β/m# kanamycin, and incubated overnight. The culture was incubated at 37 °C for one(l) hour with shaking until the O.D value reached in the scope of 0.5 to 0.7 at 600nm. Thereafter, 1 mM isopropyl-thio-β -galactopyranoside (IPTG) was added to the culture medium to facilitate the expression of the recombinant protein, and additional cultivation was made at 37 °C for five (5) hours. lm£ of the culture medium was taken and centrifuged at 14,000rpm for two (2) min. to precipitate the bacterial cells. The cell pellet was suspended in 50/t-β of 2X SDS solution [lOOmM Tris-Cl pH 6.8, 20% glycerol (w/v) , 4% SDS (w/v) , 2% 2- mercaptoethanol, 0.001% bromophenol blue] to apply in SDS-PAGE. The suspended solution was heated at 95°C for five (5) min., and then 10 tl of the solution was loaded on the well of the casted gel and electrophoresed at 20mA for five (5) hours (Mighty Small II, Hoefer, USA) . Acrylamide concentrations of the stacking gel and resolution gel which were employed, were 5% and 15% respectively, and pre-stained standard
SeeBlue(250Kda to 4kDa; NOVEX, San Diego, CA, U.S.A) or wide-ranging standard Markl2 (200kDa to 2.5kDa) were used as a standard size marker protein. After electrophoresis, the gel was stained with Coomassie brilliant blue R-250 for one(l) hour and dyed destained with decolorizing solution (5% Methanol and 7% acetic acid) for ten (10) hours.
To confirm that the expressed protein is PB14 peptide, the proteins in the electrophoresis gel, western-blotting was carried out using anti-PBl rabbit antibody (Fig.6) . Antiserum was produced by immunizing ovalbumin conjugated which was PBl peptide chemically synthesized by Bio-Synthesis, Inc. (Lewisville, TX, USA) . In Fig. 6, lane M represents the pre-stained standard SeeBlue label, lane 1 represents medium used for incubation of E. coli M15 [pREP4] which was not transformed, lane 2 represents medium used for incubation of E. coli M15 [pREP4] which was transformed with pQE30 vector, lane 3 represents medium used for incubation of E. coli M15 [pREP4] which was transformed with pBX4 vector. As depicted in Fig. 6, only the pBX4 transformed E. coli expressed the recombinant PB14 peptide represented a specific immunity with anti-PBl mouse serum.
Step 2: Identification of solubility of the expressed peptide
E. coli M15 [pREP4] which had been transformed with pBX4 vector, was incubated as the same method of
Step 1. 10ml of the culture medium was taken and centrifuged to harvest the cells. The cell pellet was suspended in 5ml of cell lysis solution (300mM NaCl, 50mM NaH2P0, lOmM imidazol pH 8.0) to obtain natural protein from the cell. After being chilled, the pellet-suspended solution was sonicated 20 cycles with ultrasonic wave in order to lyse the cells. The supernatant was taken by centrifuge at 4°C, 10,000rρm for 30 min.. The same volume of 2X SDS solution was mixed with solution and SDS-PAGE was carried out as the same method described in Step 1. After boiling each solution at 95°C for 5 min. As a result of SDS- PAGE, it was confirmed that PB1 peptide could be isolated and purified from the soluble extract A in that it was contained in the insoluble crude extract B. Step 3: purification of PB14 peptide Step 3-1: affinity chromatography Ni-NTA resin for purifying His-tagged proteins, was used to purify the recombinant peptide in Step 1. The affinity chromatography using attractive force between Ni+ saturated in resin and histidine residues at the end of the expressed protein, is a well known method for purifying interest protein easily. First of all, E. coli M15[pREP4] which had been transformed with pBX4, was inoculated in 11 of LB culture medium and incubated at 37 °C to the extent that O.D value was over 0.6 at 600nm. The ratio of LB culture medium to pBX4 vector was fifty (50) to one(l). IPTG was added in a final concentration of ImM and incubated again for five (5) hours. After incubation, the cell pellet was obtained by centrifuging the culture medium at 6,000 Xg for 30 min, and the pellet was stored at -70°C over night. The pellet thawed in ice, was suspended in dissolving solution (300mM NaCl,
50mM NaH2P04, lOmM imidazol pH 8.0) wherein 5mi of dissolving solution per 1 g of the pellet, was used.
Cells are lyzed by sonication as the method of Step 2, and then centrifuged at room temperature at 10,000 Xg for 30 min.. The same volume of buffer (8M urea, 0.1M NaH2P0, 0.01M Tris-HCl pH 8.0) as the pellet, was added for re-suspending the cellular debris and for denaturing proteins there in, and the pellet-suspended solution was treated with brief ultrasonic wave so that more proteins could be dissolved in buffer. The suspension was centrifuged at 8,000rpm for 30 min. to remove cellular debris which had not been solubilized in 8M urea. To the 4m£ of the supernatant above, lm-C of Ni-NTA resin was added at 4°C and shook 200rpm for 2 hours in order proteins containing His-tag to be captured.
Such supernatant containing protein/Ni-NTA complex was poured carefully into the chromatography column (size 2cm(id) x2.7cm(h) ) . Excess buffer was drained by opening the cap after the resin had been sunk down. The column was washed with 20ι of medium pH buffer (8M urea, 0.1M NaH2P0 0.01M Tris-HCl pH 8.0) and subsequently 20mi of another buffer (8M urea, 0.1M NaH2P04 0.01M Tris-HCl pH 6.3) in order to wash out proteins which had been non-specifically bound to the Ni-NTA resin. The target proteins containing His-tag were eluted by pouring 5mi of low pH buffer (8M urea, 0.1M NaH2P04 0.01M Tris-HCl pH 5.9) two (2) times and subsequently 5mi of strong acid buffer (8M urea, 0.1M NaH2P04 0.01M Tris-HCl pH 4.5) four (4) times, and then SDS-PAGE was used to confirm the eluted target proteins by using 15% acryamide gel (Fig. 7). In Fig. 7, lane M represents pre-stained SeeBlue size marker and lane 1 represents the purified PB14 peptide. The above purified proteins are dialyzed against PBS(8g/L NaCl, 0.2g/L KC1, 1.44g/L Na2HP04 and 0.24g/L KH2 P0 ) in order to regain their original conformations. Dialysis tube employed, was 3,500 Da in molecular weight cut-off size. During dialysis, 3L of PBS containing 2M urea was used first for 5 hours, and then 5L of PBS without urea was used two (2) times overnight .
Step 3-2: Hydrophobic chromatography
Hydrophobic chromatography was carried out in order to improve the purity of the PB14 peptide which had been obtained in Step 3-1.
Ammonium sulfate was added up to final 20% concentration little by little to the solution containing PB14 peptide, which was eluted from Ni-NTA resin in Step 3-1, and then adjusted to pH 7.0. The solution was left for three or more hours after 10% of ammonium sulfate had been melt completely, and then the solution was loaded on the phenyl sepharose column [a filling: Phenyl sepharose Fast Flow resin (Phamacia, Suweden) ; column size: 1 cm(id) x 3cm(h)]. Each fraction which was eluted from the column by pouring eluting solution (8M urea, 0. IM NaH2P04, 0.01M Tris-HCl pH 6.3) into the column at the flow rate of 0.5ml/min under the reverse gradient of ammonium sulfate from 10% to 0%, was loaded on the gel for SDS- PAGE. The fraction containing PB14 peptide was collected and dialyzed in a buffer solution to be desalted, and urea which had been used as a denaturating agent, was removed at the same time. Step 3-3: Removal of His-tag
2M urea was added to buffer solution (50mM NaCl, 20mM Tris-HCl, 2mM CaCl2 pH7.4 ) which was good for removing denaturating agent and imidazol etc. from the purified his-tagged protein and also for activating enterokinase. The dialyzed PB14 peptide which had been obtained from Step 3-2, was dialyzed again by using the above urea containing buffer to desalt the PB14 peptide, and during which, the concentration of urea was lowered little by little by repeated dialysis against urea depleted buffer. 3U/ml of enterokinase was added to the PB1 peptide-containing solution of which buffer was changed with the said second buffer, and incubated at 23°C. The solution which was taken at every hour, then was analyzed by SDS-PAGE in order to check the amount of his-tag removal from the his- tagged PB1(PB14 +his ) peptide.
Step 3-4: Ion exchange chromatography Unwanted proteins and peptides which had been produced as a result of treatment of enterokinase, were removed through ion exchange chromatography. The solution containing PB14 ~hιs peptide which had been obtained in Step 3-3, was dialyzed in dialysis buffer (2M urea, 0.1M NaH2 P0 , 0.01M Tris-HCl, pH 7.0), and the buffer was exchanged sufficiently. The solution which had been dialyzed, was loaded on the
DEAE sepharose resin (Phamacia, uppsala, Sweden).
Thereafter, the column was equilibrated with equilibrating buffer (50mM sodium phosphate buffer, 2M urea, pH 7.0) and the peptide was eluted under NaCl concentration gradient from 0 to IM by using another buffer (50mM sodium phosphate buffer, 2M urea, IM NaCl) (flow rate: 0.5ml/min) . Each fraction was recovered and target protein containing fraction were pooled. The presence of PB14 ~hls peptide was confirmed through SDS-PAGE after concentrating the compartments. Step 4: Quantitative analysis f PB14 The purified PB14 peptide which had been obtained through the same method of Step 3, was quantitatively analyzed through colorimetric analysis by using micro BCA reagent (Pierce, Rockford, USA).
Step 5: Confirmation of characteristics of the recombinant PB14 peptide
Purity of the PB1 peptides which had been purified in Step 3 and immunogenicity of them against anti-serum which had been obtained by using synthetic PB14 peptide as a antigen, were confirmed through western-blot assay by ECL (Amersham, Cleveland, UK). After SDS-PAGE (Example 2, Step 1), the gel was incubated together with PVDF membrane in buffer (0.3% Tris, 1.5% glycine, 20% methanol) at a constant voltage of 60V for three (3) hours in order for the protein in the gel to be transferred into the PVDF membrane. Then, the blotted membrane was incubated with a 5ml of blocking solution (TBS pH 7.5, 5% skim milk powder (w/v), 0.02% Tween 20) for 1.5 hours, and then was washed three times with TTBS (Tris-buffered saline solution containing 0.1% Tween 20) for 15 min.,
5 min. and 5 min. respectively. The antiserum against the peptide PBl (refers to Step 1 of Example 2) was diluted with the TTBS solution in ratio of one (1) to five thousand (5,000), and then incubated with the membrane for 1.5 hours. To confirm the purity of the
PB14 peptide, anti-serum against PB14 peptide
(Example 3) . After washing the gel with TTBS three times for 15 min., 5 min. and 5 min in turn, the membrane was incubated for 1.5 hours at room temperature with the solution in which alkaline phosphatase-F (ab) ' 2-goat anti-mouse IgG (H+L) (Zymed, San Fransisco, CA) was diluted with the TTBS solution in ratio of one(l) to one thousand(lOOO) . The membrane was washed again with TTBS three times, and then colorized by adding BCIP/NBT (5-bromo-4-chloro-3- indolyl phosphate/nitro blue tetrazolium(Sigma) ) . BCIP/NBT solution was removed using TTBS solution after staining. As a result of western-blotting analysis, the expressed PB1 peptide could be recognized with the anti-PBl4 serum.
In case of ECL, PVDF membrane (Gel an Science, BioTraceR) was used instead of nitrocellulose membrane. In addition, the first antibody was used in ratio of one(l) to ten thousand(10, 000) and HRP-conjugated rabbit anti-mouse IgG (Pierce, Rockford, IL, U.S.A.) was used as the second antibody in ratio of one(l) to ten thousand(10,000) . 1 ml of solution A of ECL+Plus western-blot agent (Amersham) per 25 ml of solution B, was used in color reaction. When color was generated sufficiently, the membrane was inserted into film cassette for 5, 10, 20 and 30 seconds respectively to be exposed to the film so that the bands on the gel could be detected (Fig. 8) . In Fig. 8, lane M represents a ECL detecting label (Gibco BRL) and lane 1 represents the PB14 peptide. As the result from Fig. 8, the expressed PB14 peptide could be recognized with the anti-PBl4 serum.
In addition, the result of western-blot analysis on which the PBI4 peptide using polyclonal antibody isolated from rabbit serum by using Protein G column (Bio-Rad, USA), gave the same result.
Example 5: Preparation of anti-PBl4 peptide mouse antibody The PB14 peptide used herein was the PBl4 "his peptide from which his-tag was removed, in step 3-3 of example 2.
Step 1: Ligation between PB1 peptide and OVA As a carrier protein, ovalbumin (OVA) , was added to the purified PB14 peptide in Step 3 in Example 2, in molar ration of one(l) to ten (10), and was incubated for one (1) hour at 4°C. To the PBI4 peptide-ovalbumin solution, 2% (v/v) glutaraldehyde was added with the same volume, and incubated for one (1) hour with continuous shaking. Then glycine was added to the reaction mixture until final concentration is to be 0.2M to stop the reaction proceeding therein.
After the reaction, the remaining glutaraldehyde- glycine in reaction mixture, were removed by dialysis using MWCO 12,000-14,000 dialysis membrane (SpectrumR, Dominguez, CA, USA) .
Step 2. Immunization of mouse The peptide with which OVA was linked in Step 1, was concentrated and used to immunize mouse. The amount of the antigen to be injected to the mouse, was 5ug which was the amount of PBI4 peptide before linked with OVA. The antigen which was emulsified with the same amount of an adjuvant, was injected to intraperitoneum cavity of the mouse in amount of 0.2ml. Complete Freund's Adjuvant (CFA) was used as the adjuvant of the first injection, and Incomplete Freund's Adjuvant (IFA) was used as the adjuvant at the boosting immunization for two (2) times by two (2) weeks interval. In control mouse, BSA (bovine serum albumin) was injected.
After five (5) days from the final injection, 1ml of blood was taken from mouse by cardiac puncture and the blood was clotted for 30 min. at 37 °C. Then, the blood was centrifuged for 30min. at 4°C, 2500xg and the clot was removed from the blood. The supernatant (i.e., blood serum) was incubated overnight at 4°C for the remaining blood coagulants to be concentrated completely, and centrifuged for 20min. at 10,000xg. The resulting supernatant was aliquoted into several tubes. The blood serum which was to be used in experiment, was stored at 4°C, and the remainders were stored at -20°C .
Step 3. Measurement of avidity of anti-PBl antibody by indirect ELISA
The avidity of the antibody was measured by using blood serum obtained in Step 2. lOOul of PB14 peptide was distributed into each well of 96 well micro-titer plate (Flacon: pro-binding) and left alone at 4°C for 6 hours or more, and then washed three (3) times with
TTBS (Tirs buffer saline solution containing 0.05% Tween 20) . 200ul of blocking solution (1% BSA in TTBS) was added to each well and incubated at 37 °C for one
(1) hour, and then washed three (3) times with TTBS. lOOul of the isolated serum which had been diluted with the blocking solution in ratio of one(l) from 102 to 105, was added to the reaction solution and incubated at 37 °C for 1 hour, and then washed three (3) times with 200ul of TTBS. lOOul of HRP-linked goat anti-rabbit IgG antibody (Pierce, Rockford, IL) which had been diluted with the blocking solution in ratio of one(l) to 103, was added to the reaction solution and incubated at 37 °C for 1 hour, and washed three (3) times with 200ul of TTBS. Solution A of the HRP substrate kit (Bio-Rad) was mixed with solution B of the same in ratio of nine (9) to one (1) . lOOul of the resultant mixture was added to the reaction solution and colorized for thirty (30) min., and then optical absorbency for the reaction mixture was measured at 405nm by using ELISA leader (EL312e, Bio-Tek Ins.) (Fig.9). In Fig. 9, it was confirmed that the mouse antibody specific for PB14 peptide could be applied to western-blot and ELISA analysis by one (1) thousand fold (3.0 of the X axis in figure).
Example 6: Anti-obesity effect of PB14 vaccine by using a mouse model. Step 1: Induction of obesity in a mouse
5 week-old ICR mice (Korea Center for Animal
Experiment Ltd., Seoul, Korea) were used herein. The mice were raised in a breeding farm in which temperature was kept from 17°C to 25°C, and fed to a mixed feed (Sam Yang Feed Ltd., Seoul, Korea,
[ingredient: water 11.8% or more, protein 20.0% or more, crude lipid 3.0% or more, crude fiber 10.0% or less, crude ash 10.0% or less, calcium 0.6% or less and phosphorus 0.4% or more]). Goldthioglucose (GTG) was administered to the mice to induce obesity. GTG have a role of inducing desensitization of ventero- medial hypothalamic nuclei (VMH) . Therefore, the mice administered with GTG did not feel satiated and always had a desire to eat. The GTG used herein is very unstable compound which is easily degraded in water or moisture. Therefore, lOOmg of GTG (Sigma, Inc.) was diluted with 1ml of sesame oil (Sigma Inc.), and was used as the same method of Brecher et al(Brechere G. and Waxier, S. H. Proc. Soc. Exp . Biol . Med. , 70 : 498- 501(1949)) in order for a proper amount of GTG to be administered.
The mice were distributed to prepare a test (twenty (20) mice) .and a control group (four (4) mice), and 25ml of GTG was injected to the test group whereas the control was injected with nothing.
Body weight of the mice of the test group was measured prior to experiment and the mice of which deviation of body weight was not significant, were selected and applied to experiment. Body weight of the mice measured after one (1) week after GTG injection, was in the range from 26.5 to 29.5grams.
Seven mice of -the GTG-injected group were induced to be obese whereas the remainder was not. The mice which were not induced to be obese, was injected again with GTG, then all the mice were induced to be obese. All of the obesity-induced mice were distributed in three (3) group. A week later from second GTG injection the PB14 peptide was injected to the mice of test group 1 consisting of seven (7) mice as the same method in Step 2 of Example 3. In addition, the mice (test group 2 containing seven (7) mice) of another group of the three, were injected with ovalbumin instead of PBI4 peptide as a mock experiment, and vaccine was not injected to the other group (test group 3 containing si (6) mice) to induce obesity. On the other hand, 0.2ml of PBS was injected to the control group to be compared with the test groups to confirm the effect of the vaccine of the present invention.
In addition, feed used herein was mixed with the yolk of an egg and dried at 50°C to induce intake of cholesterol so that the level of cholesterol could increase in mouse serum. Feed was also provided enough for disease related to the level of cholesterol to be caused. Body weight of the mouse was measured everyday. As depicted in Fig. 10, body weight of the vaccine'-injected mice of test group l(-A-A-), increased from 27.7±0.4g to 52.2±1.7g after twelve weeks (12) of GTG injection. The data justify a conclusion that there was no significant difference of an increase in body weight between the test group 1 and the control group (-0-0-) . However, body weight of the mice of both the test group 2 (-•-•-) in which ovalbumin was injected after being obese and the test group (-■-■-) in which no vaccine was injected after the induction of obesity, increased continuously from 28.3±0.5g to 68.9±2.8g. Therefore, it was confirmed that obesity could be inhibited by injection of PBI4 peptide vaccine.
In Fig. 10, Gl and G2 represent the time of GTG injection and VI, V2 and V3 represent the time of injection of PBI4 peptide vaccine.
Fig. 11 represents appearance of the obesity- induced mice. 20-week old mouse of the test group 1 (Fig.11a: normal mouse) was compared with 20-week old mouse of the test group 3 (Fig. llb:obese mouse). As depicted in Fig. 11, it was confirmed that the vaccine of the present invention was effective in inhibiting obesity.
Step 2: Measurement of the level of cholesterol in blood. After the first GTG injection, blood cholesterol level of 12-week old mouse of the control group was compared with that of 12-week old GTG-injected mouse of the test group 1 and 2. Concentration of total cholesterol, triglyceride, HDL-cholesterol and LDL- cholesterol was measured through an enzymatic method by using Cholestezyme-V, Triglyzyme-V, HDL-C555 (Shin
Yang Chemicals, Seoul, Korea) and LDL-EX kit(Denka
Bio-Research, Ltd., Tokyo, Japan). In each experiment, a standard curve for O.D value was prepared by using standard Calibrater-D (Denka Bio-Research, Ltd., Tokyo,
Japan) to decrease an experimental error. O.D value for the interest was calculated based on the calibration curve to confirm the concentration and content of the lipid, the result was depicted in Table
1 and Fig. 12.
Figure imgf000033_0001
As depicted in Table 1 and Fig. 12, as the result of the induction of obesity, it was confirmed that there was no significant difference in the content of cholesterol of both the test group and the control did not increase whereas overall blood concentration of total cholesterol, HDL-C and LDL-C increased in small amount (Fig.12) .
Industrial Applicability
The vaccine composition of the present invention, which contains mimetic peptide for the epitope of apolipoprotein B-100, the concatemers and modified peptide thereof, can be inhibit occurrence of obesity without causing auto-immunity in organism.
Therefore, LDL-related circulatory disease can be treated by vaccine of the present invention more effective than the transitory and high-priced conventional method in which cholesterol metabolism- related enzyme was inhibited.
While the present invention has been particularly shown and described with reference to particular examples thereof, it will be understood by those skilled in the art that various change in form and details may be conceived, therefrom without departing from the spirit and scope of the present invention as defined by the appended claim.

Claims

What is claimed is :
1. A mimetic peptide for the epitope of apolipoprotein B-100 and concatemer thereof of SEQ. ID. No. 1.
2. The concatemer of mimetic peptide according to Claim 1, wherein said concatemer comprises one(l) to fifteen (15) said mimetic peptides.
3. The concatemer of mimetic peptide according to Claim 1, wherein said concatemer comprises four (4) said mimetic peptides linked consecutively.
4. The mimetic peptide and concatemer thereof according to Claim 1, wherein amino acid sequence of said mimetic peptide is modified by a method selected from the group consisting of addition, deletion and chemical substitution.
5. A mimetic peptide for the epitope of apolipoprotein B-100 of SEQ. ID. No. 2.
6. The mimetic peptide according to Claim 5, wherein said concatemer comprises one(l) to fifteen (15) said mimetic peptides.
7. The concatemer of mimetic peptide according to Claim 5, wherein said concatemer comprises four (4) said mimetic peptides linked consecutively.
8. The mimetic peptide according to Claim 5, wherein amino acid sequence of said mimetic peptide is modified by a method selected from the group consisting of addition, deletion and chemical substitution.
9. A mimetic peptide for the epitope of apolipoprotein B-100 of SEQ. ID. No. 3.
10. The concatemer of mimetic peptide according to Claim 9, wherein said concatemer comprises one(l) to fifteen (15) said mimetic peptides.
11. The concatemer of mimetic peptide according to Claim 9, wherein said concatemer comprises four (4) said mimetic peptides linked consecutively.
12. The mimetic peptide according to Claim 9, wherein amino acid sequence of said mimetic peptide is modified by a method selected from the group consisting of addition, deletion and chemical substitution.
13. A vaccine composition for treatment of obesity, which comprises a peptide selected from the group of consisting of the mimetic peptides for the epitope of apolipoprotein B-100 of SEQ. ID. No.l, SEQ. ID. No.2 and SEQ. ID. No. 3, concatemer thereof, modified peptides thereof and mixtures thereof.
14. The vaccine composition according to Claim 13, said vaccine composition is administered by intradermal injection.
15. The vaccine composition according to Claim 13, wherein type of said vaccine composition is selected from the group consisting of tablets, pills, granules, cachets, elixirs, suspensions, emulsion, solution, syrups, aerosols, soft or hard gelatin capsules, sterilized injectable solution and sterilized powder.
16. A process for preparing a mimetic peptide for the epitope of apolipoprotein B-100, concatemer and the modified peptide thereof, which comprises i) a step for inserting DNA which encodes genetic information of a mimetic peptide for the epitope of apolipoprotein B-100, the concatemer and the modified peptide thereof of SEQ. ID. No. 1, SEQ. ID. No. 2 and SEQ. ID. No. 3 into a vector; ii) a step for transforming host cells with the vector obtained in step i) and for incubating the same; iii) a step for isolating said mimetic peptide for the epitope of apolipoprotein B-100, concatemer and the modified peptide thereof from the host cell.
17. A DNA encoding a polypeptide composed of four (4) mimetic peptide for the epitope of apolipoprotein B-100 of SEQ. ID. No. 1 linked consecutively.
18. An expression vector which comprises DNA fragment encoding a polypeptide composed of four (4) mimetic peptides for the epitope of apolipoprotein B- 100 of SEQ. ID. No. 1 linked consecutively.
PCT/KR2001/001492 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same WO2002020040A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP01965715A EP1315517B1 (en) 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
JP2002524523A JP2004508029A (en) 2000-09-04 2001-09-04 Mock peptides against epitopes of apolipoprotein B-100, their conjugates or variants and vaccine compositions containing them
EEP200200238A EE200200238A (en) 2000-09-04 2001-09-04 Mimetic Peptides of the Apolipoprotein B-100 Epitope, Concatemer and Modified Peptides, and Vaccine Compositions Containing Them
BR0107175-0A BR0107175A (en) 2000-09-04 2001-09-04 Mimetic peptides for apolipoprotein epitope b-100, concatemero and their modified peptides, and vaccine composition comprising the same
AT01965715T ATE485053T1 (en) 2000-09-04 2001-09-04 MIMETIC PEPTIDES FOR EPITOPE OF APOLIPOPROTEIN B-100, CONCATEMER AND MODIFIED PEPTIDES THEREOF, AND THE VACCINE COMPOSITION CONTAINING SUCH PEPTIDES
SK631-2002A SK6312002A3 (en) 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein b-110, concatemer and modified peptides thereof, and the vaccine composition comprising the same
HU0203251A HUP0203251A2 (en) 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
CA002389739A CA2389739A1 (en) 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
AU86286/01A AU8628601A (en) 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
DE60143300T DE60143300D1 (en) 2000-09-04 2001-09-04 MIMETIC PEPTIDES FOR THE EPITOPH OF APOLIPOPROTEIN B-100, CONCATEMER AND MODIFIED PEPTIDES THEREOF, AND THE VACCINATE COMPOSITION WITH SUCH PEPTIDES
IL14937901A IL149379A0 (en) 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
MXPA02004505A MXPA02004505A (en) 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same.
BG106655A BG106655A (en) 2000-09-04 2002-04-25 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition
NO20022147A NO20022147L (en) 2000-09-04 2002-05-03 Mimetic peptides for apolipoprotein B-100 epitopes, concatams and modified peptides thereof, and vaccine composition comprising the same
US10/378,707 US6825318B2 (en) 2000-09-04 2003-03-04 Mimetic peptides for an epitope of apolipoprotein B-100, concatemers of the peptides, and modified peptides, and compositions comprising the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR2000/0052055 2000-09-04
KR20000052055 2000-09-04
KR10-2001-0054005A KR100472841B1 (en) 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
KR2001/0054005 2001-09-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/378,707 Continuation US6825318B2 (en) 2000-09-04 2003-03-04 Mimetic peptides for an epitope of apolipoprotein B-100, concatemers of the peptides, and modified peptides, and compositions comprising the same

Publications (1)

Publication Number Publication Date
WO2002020040A1 true WO2002020040A1 (en) 2002-03-14

Family

ID=26638363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2001/001492 WO2002020040A1 (en) 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same

Country Status (18)

Country Link
US (1) US6825318B2 (en)
EP (1) EP1315517B1 (en)
JP (1) JP2004508029A (en)
CN (1) CN1231262C (en)
AU (1) AU8628601A (en)
BG (1) BG106655A (en)
BR (1) BR0107175A (en)
CA (1) CA2389739A1 (en)
CZ (1) CZ20021571A3 (en)
EE (1) EE200200238A (en)
HU (1) HUP0203251A2 (en)
IL (1) IL149379A0 (en)
LT (1) LT4989B (en)
MX (1) MXPA02004505A (en)
NO (1) NO20022147L (en)
RU (1) RU2313536C2 (en)
SK (1) SK6312002A3 (en)
WO (1) WO2002020040A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756143A1 (en) * 2004-03-18 2007-02-28 SJ Biomed Inc. Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
US20070054298A1 (en) * 2005-08-12 2007-03-08 Kent Kirshenbaum Methods for enzyme-mediated coupling of oligomers
CN103520713A (en) * 2013-10-16 2014-01-22 西北农林科技大学 Recombinant vaccine of ApoB100 yeast as well as preparation method and application thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636356A1 (en) * 2003-06-11 2006-03-22 Schering Aktiengesellschaft Novel modified corin molecules having substitute activation sequences and uses thereof
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
WO2007075335A2 (en) * 2005-12-16 2007-07-05 The Regents Of The University Of California Modulation of in utero immune programming
US20110002955A1 (en) * 2006-09-25 2011-01-06 Sj Biomed Inc. Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
EP3463416A1 (en) 2016-05-31 2019-04-10 CardioVax, LLC Methods for diagnosing and treating systemic lupus erythematosus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975792B1 (en) * 1997-03-04 2007-10-10 Savient Pharmaceuticals, Inc. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
AU2801299A (en) * 1998-03-04 1999-09-20 Bio-Technology General Corporation Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
HUP0300099A3 (en) * 2000-03-03 2004-10-28 Smithkline Beecham Biolog Vaccine for the treatment of artherosclerosis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALVING C. AND WASSEF N.: "Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism", IMMUNOLOGY TODAY, vol. 20, no. 8, 1999, pages 362 - 366, XP004177364 *
ALVING C. ET AL: "Antibodies to cholesterol: biological implications of antibodies to lipids", CURR. TOP. MICROBIOL. IMMUNOL., vol. 210, 1996, pages 181 - 186, XP002923267 *
ALVING C. ET AL: "Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation", J. LAB. CLIN. MED., vol. 127, no. 1, 1996, pages 40 - 49, XP001095396 *
KNOTT T. ET AL: "Complete protein sequence and identification of structural domains of human apolipoprotein B", NATURE, vol. 323, no. 6090, 1986, pages 734 - 738, XP002133890 *
SOUED M. AND MANSBACH C.: "Chylomicron remnant uptake by enterocytes is receptor dependent", AM. J. PHYSIOL., vol. 270, 1996, pages G203 - G212, XP002980789 *
STADLER M. ET AL: "Mimotope and anti-idiotype vaccines to induce an anti-IgE response", INT. ARCH. ALLERGY IMMUNOL., vol. 118, no. 2-4, 1999, pages 119 - 121, XP000916451 *
STEWARD M. ET AL: "A mimotope from a solid-phase peptide library induces a measles virus-neutralization and protective antibody response", J. VIROL., vol. 69, no. 12, 1995, pages 7668 - 7673, XP002980775 *
YOUNG S.: "Recent progress in understanding apolipoprotein B", CIRCULATION, vol. 82, no. 5, 1990, pages 1574 - 1594, XP002980787 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756143A1 (en) * 2004-03-18 2007-02-28 SJ Biomed Inc. Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
JP2008500813A (en) * 2004-03-18 2008-01-17 エスジェイ バイオメッド インコーポレイテッド Anti-obesity immunogenic hybrid polypeptide and anti-obesity vaccine composition containing the same
EP1756143A4 (en) * 2004-03-18 2010-10-06 Sj Biomed Inc Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
US7829667B2 (en) * 2004-03-18 2010-11-09 SJ Biomed, Inc. Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
US20070054298A1 (en) * 2005-08-12 2007-03-08 Kent Kirshenbaum Methods for enzyme-mediated coupling of oligomers
CN103520713A (en) * 2013-10-16 2014-01-22 西北农林科技大学 Recombinant vaccine of ApoB100 yeast as well as preparation method and application thereof
CN103520713B (en) * 2013-10-16 2015-10-28 西北农林科技大学 A kind of ApoB100 yeast-recombinant vaccine and its preparation method and application

Also Published As

Publication number Publication date
SK6312002A3 (en) 2002-09-10
JP2004508029A (en) 2004-03-18
HUP0203251A2 (en) 2003-01-28
AU8628601A (en) 2002-03-22
EP1315517A4 (en) 2005-02-09
CN1392798A (en) 2003-01-22
US6825318B2 (en) 2004-11-30
IL149379A0 (en) 2002-11-10
NO20022147D0 (en) 2002-05-03
CA2389739A1 (en) 2002-03-14
NO20022147L (en) 2002-05-03
CZ20021571A3 (en) 2002-09-11
EP1315517B1 (en) 2010-10-20
BG106655A (en) 2004-08-31
BR0107175A (en) 2002-07-02
RU2003109439A (en) 2004-07-20
RU2313536C2 (en) 2007-12-27
CN1231262C (en) 2005-12-14
EP1315517A1 (en) 2003-06-04
US20030211997A1 (en) 2003-11-13
EE200200238A (en) 2003-06-16
LT2002051A (en) 2002-09-25
LT4989B (en) 2003-01-27
MXPA02004505A (en) 2004-09-10

Similar Documents

Publication Publication Date Title
Ståhl et al. A dual expression system for the generation, analysis and purification of antibodies to a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA
US6410022B1 (en) Modulation of cholesteryl ester transfer protein (CETP) activity
KR100500782B1 (en) Expression system of heterologous antigens as fusion proteins
FI110615B (en) Process for producing protein which forms a modified capsid
JP3771265B2 (en) Moraxella high molecular weight major outer membrane protein
Skeiky et al. Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients.
Leberer et al. Molecular cloning and expression of cDNA encoding the 53,000-dalton glycoprotein of rabbit skeletal muscle sarcoplasmic reticulum
EP1315517B1 (en) Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
US4521334A (en) Synthetic polypeptide fragments
RU2341534C2 (en) Anti-obesity immunogenic hybrid polypeptide and based vaccine composition
Sjölander et al. Immunogenicity and antigenicity in rabbits of a repeated sequence of Plasmodium falciparum antigen Pf155/RESA fused to two immunoglobulin G-binding domains of staphylococcal protein A
Sjölander et al. High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA
CA2069106A1 (en) Chimeric proteins
AU2007200834B2 (en) Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
KR100472841B1 (en) Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
TRZYNA et al. Schistosoma mansoni: genetic non‐response to p40, the major protein antigen of the egg, reveals a novel mechanism enhancing IgM production during infection
WO2001027144A2 (en) Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
CAvELIER et al. Plasmodium falciparum: The Immune Response in Rabbits to the Clustered Asparagine-Rich Protein (CARP) after lmmunization in Freund's Adjuvant or Immunostimulating Complexes (ISCOMs)
Sjolander et al. Plasmodium falciparum: The Immune Response in Rabbits to the Clustered Asparagine-Rich Protein (CARP) after Immunization in Freund′ s Adjuvant or Immunostimulating Complexes (ISCOMS)
WO2024111633A1 (en) Production of antibodies against protein
Mercereau‐Puijalon et al. Cross‐reaction of antibodies to the nine‐amino acid repeats of Plasmodium falciparum antigen 11.1 with human serum albumin
JPH02264731A (en) Eimeria film-combining protein immunogen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2002 200200563

Country of ref document: RO

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001965715

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 106655

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 86286/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 149379

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2002 20020075

Country of ref document: LV

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2002/03383

Country of ref document: ZA

Ref document number: 200220020075

Country of ref document: LV

Ref document number: 518626

Country of ref document: NZ

Ref document number: 2002051

Country of ref document: LT

Ref document number: 200203383

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2002 524523

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2389739

Country of ref document: CA

Ref document number: IN/PCT/2002/00449/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2002-1571

Country of ref document: CZ

Ref document number: PA/a/2002/004505

Country of ref document: MX

Ref document number: 6312002

Country of ref document: SK

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 018030572

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: PV2002-1571

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2002051

Country of ref document: LT

WWG Wipo information: grant in national office

Ref document number: 2002051

Country of ref document: LT

WWE Wipo information: entry into national phase

Ref document number: 10378707

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2003109439

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 2001965715

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002051

Country of ref document: LT

WWR Wipo information: refused in national office

Ref document number: PV2002-1571

Country of ref document: CZ